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Abstract 
 
The role of oxidative stress (OXS) due to myocardial nitric oxide synthase (NOS) uncoupling 
related to oxidative depletion of its cofactor tetrahydrobiopterin (BH4) emerged in the 
pathogenesis of heart failure with preserved ejection fraction (HFPEF). 
We determined the prevalence of 6 single nucleotide polymorphisms (SNPs) of genes 
encoding enzymes related to OXS, BH4 metabolism and NOS function in >60-year-old 94 
patients with hypertension and 18 age-matched controls with normal EF.  Using 
echocardiography 56/94(60%) patients with hypertension had left ventricular (LV) diastolic 
dysfunction (HTDD+ group), 38/94(40%) patients had normal LV diastolic function (HTDD- 
group).  Four SNPs (rs841, rs3783641, rs10483639, rs807267) of guanosine triphosphate 
cyclohydrolase-1, the rate limiting enzyme in BH4 synthesis, 1 (rs4880) of manganese 
superoxide dismutase, and 1 (rs1799983) of endothelial NOS genes were genotyped using real 
time PCR method and Taqman probes.  Protein carbonylation (PC), BH4 and total biopterin 
levels were measured from plasma samples.  No between-groups difference in minor allele 
frequency (MAF) of SNPs was found.  We calculated a genetic score indicating risk for OXS 
based on the MAFs of the SNPs.  A high genetic risk for OXS was significantly associated 
with HTDD+ even after adjustment for confounding variables [OR(95%CI):4.79(1.12-20.54); 
p=0.035].  In both patient groups PC (p<0.05 for both), plasma BH4 (p<0.01 for both) and in 
the HTDD+ group total biopterin (p<0.05) increased vs. controls.  In conclusion, in patients 
with hypertension and normal EF, a potential precursor of HFPEF, a partly genetically 
determined increased OXS seems to be associated with the presence of LV diastolic 
dysfunction. 
key words: hypertension, heart failure with preserved ejection fraction, oxidative stress 
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Abbreviations 
 
BH2=7,8-dihydrobiopterin 
BH4=tetrahydrobiopterin 
BMI=body mass index 
BSA=body surface area 
EF=ejection fraction 
GTPCH-1=guanosine-triphosphate-cyclohydrolase-1 
HFPEF=heart failure with preserved ejection fraction 
IVRT=isovolumic relaxation time 
LV=left ventricular 
LVM=left ventricular mass 
MAF=minor allele frequency 
MnSOD=manganese superoxide dismutase 
NO=nitric oxide 
NOS=nitric oxide synthase 
O2
-.
=superoxide anion radical 
OR=odds ratio 
OXS=oxidative stress 
PC=protein carbonylation 
SNP=single nucleotide polymorphism 
SOD=superoxide dismutase 
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Introduction 
 
Hypertension is the most common underlying cause of heart failure with preserved 
ejection fraction (HFPEF), which partly or entirely accounts for 78-88% of HFPEF cases
1-3
.  
The transition of hypertensive heart disease to HFPEF is characterized by progressive left 
ventricular (LV) hypertrophy and deterioration of LV diastolic and atrial function
4
.  Oxidative 
stress (OXS) mainly due to myocardial nitric oxide synthase (NOS) uncoupling as a 
consequence of the depletion of the NOS cofactor tetrahydrobiopterin (BH4) may play a 
decisive role in this transition process
5-8
. 
Both essential hypertension and LV diastolic dysfunction, the latter is considered the 
main pathophysiologic mechanism of HFPEF, are partly determined genetically by a large 
number of genes, each exerting only a small effect
9,10
.  Thirty
11
 or 30-60 %
12
 of blood 
pressure variation can also be attributed to genetic influences, and environmental exposures 
account for the remaining 40-70%. 
In this study we sought to investigate gene polymorphisms related to both 
hypertension or endothelial dysfunction and OXS or BH4 metabolism in order to assess 
whether there is a genetic predisposition to OXS in patients with hypertension and normal 
ejection fraction (EF), and if yes, how it is associated with LV diastolic dysfunction in these 
patients.  To this end, we determined the prevalence of 6 single nucleotide polymorphisms 
(SNPs) of genes encoding enzymes related to OXS, BH4 metabolism and NOS function.  The 
prevalence of 4 SNPs (rs841 C>T, rs3783641 A>T, rs10483639 C>G and rs8007267 G>A) of 
guanosine triphosphate cyclohydrolase-1 (GTPCH-1), the rate limiting enzyme in BH4 
synthesis, 1 (rs4880 T>C) of manganese superoxide dismutase (MnSOD) and 1 (rs1799983 
G>T) of endothelial NOS (NOS3) genes were determined. 
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The studied 4 GTPCH-1 SNPs are strongly linked to each other and later it was 
referred as the „pain-protective” GTPCH-1 haplotype13.  The minor alleles of these SNPs are 
associated with reduced pain sensitivity, mildly increased blood pressure and heart rate due to 
decreased BH4 production [and consequential decreased nitric oxide-mediated endothelial 
function and increased vascular superoxide anion radical (O2
-.
) production], which mainly 
manifests in pathophysiological situations when BH4 production would be normally increased 
due to upregulation of GTPCH-1, e. g. at inflammatory sites or in injured neurons
13
 or in 
blood vessels exposed to high blood pressure, high cholesterol or other cellular stress 
factors
13
. 
Manganese superoxide dismutase (MnSOD) encoded by SOD2 gene is an enzyme 
catalyzing dismutation of O2
-.
 to hydrogen peroxide and is an important substituent of cellular 
enzymatic antioxidant defense against OXS
14
.  MnSOD proved to be essential for the survival 
of aerobic organisms, demonstrated by the extremely short survival of MnSOD knockout 
mice, which died shortly after birth with dilated cardiomyopathy and neurodegeneration
14
.  
The extensively investigated rs4880 SNP (T>C change at nucleotide level) causes a 
substitution of valine (GTT) with alanine (GCT) at codon 16.  The alanine variant of MnSOD 
has an α-helical mitochondrial targeting domain, whereas the valine variant of MnSOD has a 
β-pleated sheet conformation14-16.  This conformational difference results in a more efficient 
transport of alanine variant of MnSOD into mitochondria than the valine variant
14-16
, which 
results in a more efficient protection against OXS.  The homozygote Ala/Ala genotype has a 
30-40% higher MnSOD activity than its Val/Val counterpart
14-16
.  The alanine variant is 
associated with decreased risk for coronary artery disease, myocardial infarction and 
atherosclerosis, whereas the Val/Val genotype is an independent genetic risk factor for 
coronary artery disease and vasospastic angina
15-17
. 
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Endothelial nitric oxide synthase (NOS3=eNOS) synthesizes nitric oxide (NO) from 
L-arginine, which is a key mediator of endothelial function and reduces OXS by scavenging  
O2
-.
.  The 894G/T substitution within exon 7 in the rs1799983 G>T SNP of NOS3 gene leads 
to a 298 Glu/Asp substitution in the mature protein.  It has been reported that the 298Asp 
variant has an enhanced susceptibility to intracellular proteolytic cleavage compared with the 
298Glu variant, and has been associated with a lower eNOS activity and reduced generation 
of NO
18,19
.  However, other studies have not confirmed these associations
20
.  The minor allele 
variant of the rs1799983 G>T SNP of NOS3 gene may be associated with endothelial 
dysfunction and increased risk for coronary artery disease
21-23
.  
 
Materials and Methods 
 
Patients 
 
The study was conducted from December 2007 to July 2012 at the 3
rd
 Department of 
Medicine, Semmelweis University, Budapest. The study complied with the Declaration of 
Helsinki, and was approved by the Institutional Committee on Human Research. All 
participants signed an informed consent. We designed to prospectively enroll 100 
hypertensive patients with normal LVEF (> 50%) and 40 normotensive, healthy controls ≥ 60 
years old over 3 years, but even during an extended period we could enroll only 94 
hypertensive patients and 18 age-matched controls.  Each patient was followed up for at least 
one year and 44 patients for 3 years (the average follow-up period was 23.3 ± 12.5 months). 
Each patient underwent a physical examination, an ECG, a detailed echocardiography, a 
carotid ultrasound and a chest X-ray at annual follow-up examinations. This study is a part of 
a multipurpose study conducted in the same patients with the objective to provide new 
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insights into the pathogenesis of HFPEF by investigating its most common precursor state 
hypertension with normal EF.  We conducted 3 studies: 1) investigating the role of oxidative 
stress, inflammation, prothrombotic state and neuroendocrine activation in the pathogenesis of 
HFPEF; 2) investigating the genetic predisposition to oxidative stress, 3) testing the MacIver-
Townsend hypothesis explaining the mechanism of normal LVEF despite reduced 
longitudinal LV systolic function.. 
Eight patients quit the study, and nine patients fulfilled the exclusion criteria (HFPEF 
developed in two of them) during follow up.  We could not perform genetic analysis in 5 
patients [2 control and 3 hypertensive patients (1 with normal LV diastolic function and 2 
with LV diastolic dysfunction)] for various reasons, including bad quality of isolated DNA or 
withdrawn approval for genetic testing.  Hypertension was defined by a systolic blood 
pressure > 140 mmHg and/or a diastolic blood pressure > 90 mmHg, or by antihypertensive 
pharmacotherapy. Blood pressure values are the average of three readings obtained using 
standard procedures. 
Exclusion criteria included diabetes mellitus, more than a mild degree valvular or 
congenital heart disease, the presence of electrical pacemakers or implantable cardiac 
defibrillators, prior cardiovascular surgery, an established history of coronary heart disease, 
prior or ongoing atrial tachyarrhythmias, prior or manifest heart failure, any malignant or 
immunological disease, anticoagulant or antioxidant treatment, or conditions associated with 
acute inflammation or stress. 
 
Measurement of oxidative stress parameters 
 
All measurements were carried out from plasma samples.  Protein carbonylation (PC) 
assays were based on the photometric method of Levine et al.
24
.  Plasma tetrahydrobiopterin 
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(BH4) level was measured using high performance liquid chromatography based on the 
method of Fukushima and Nixon
25
 and modified by Fekkes and Voskuilen-Kooijman
26
.  The 
BH4 level was calculated from the difference between total biopterin [BH4 plus 7,8-
dihydrobiopterin (BH2) plus biopterin] level determined by acid iodine oxidation of BH2 and 
BH4 to biopterin and the alkaline-stable oxidized biopterin level (BH2 plus biopterin) obtained 
using alkaline iodine, which oxidizes only BH2 to biopterin.  These methods were described 
in a more detailed way earlier
27
. 
 
Molecular biology methods 
 
The total genomic DNA was isolated from peripheral blood using a QIAamp DNA Blood 
Mini Kit (QiagenGmbH, Hilden, Germany), DNA Isolation Kit for Mammalian Blood 
(Roche, Mannheim, Germany; Indianapolis, IN, USA).  Genotypes for the rs841, rs3783641, 
rs10483639, rs8007267, rs4880 and rs1799983 polymorphisms were determined using a 
predesigned Taqman allelic discrimination assay (C_9866639_10, C_25800745_10, 
C_30444867_20, C_1545138_10, C_8709053_10 and C_3219460_20 respectively). The 
assay was carried out according to the manufacturer’s instructions (Applied Biosystems, 
Applied Biosystems Group, 850 Lincoln Center Drive, Foster City, CA) on a 7500 Fast Real 
Time PCR System (Applied Biosystems). 
 
Calculation of minor allele frequency and genetic score 
 
Minor allele frequency (MAF) was calculated by dividing the total number of minor 
alleles by the total number of alleles in each group.   
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We devised a genetic score based on the MAFs of the investigated SNPs indicating the 
predisposition of patients to OXS.  The calculation of the genetic score was based on the total 
number of minor alleles in each subject.  In the case of rs1799983 NOS3 SNP the presence of 
minor allele predisposes to OXS, therefore the homozygotes of each major allele received a 
score 0, each minor allele heterozygotes received a score 1 and each minor allele 
homozygotes received a score 2.  In the case of rs4880 MnSOD SNP, as the presence of 
minor allele is protective against OXS, an inverse score was used: major allele homozygotes 
received a score 2, minor allele heterozygotes received a score 1 and minor allele 
homozygotes received a score 0.  Since the inheritance of the 4 GTPCH-1 SNPs are strongly 
linked, and 2 haplotypes are representing 91% of the patients, therefore we calculated a 
haplo4 score the following way: if the number of GTPCH-1 minor alleles was 0 or 1 the score 
was 0, if the number of GTPCH-1 minor alleles was >2, the score was 1.  Thus, theoretically 
the total value of the genetic score could have ranged from 0 to 5.  Patients were divided into 
two groups according to the total value of the genetic score: 1.) patients with low genetic risk 
for OXS with a total genetic score value of 0 or 1; and 2.) patients with high genetic risk for 
OXS with a total genetic score value of >2.  This definition of patients with low and high 
genetic risk for OXS is somewhat arbitrary, however our precalculations using other 
definitions as well showed that this definition could best demonstrate the between-groups 
difference in genetic risk for increased OXS. 
 
Echocardiography 
 
Standard echocardiography 
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Echocardiographic imaging was carried out using a Philips iE33 system (Philips 
Ultrasound, Bothell, WA, USA).  Cardiac dimensions and wall thicknesses were measured 
from two-dimensionally guided M-mode tracings according to the recommendations of the 
American Society of Echocardiography
28
.  LV mass was computed by the Devereux-modified 
cube formula
29
.  The biplane Simpson method was applied to calculate LV end-diastolic and 
end-systolic volumes, stroke volume, and LVEF.  LV diastolic function was assessed using 
the combination of transmitral Doppler flow, pulmonary venous flow, isovolumic relaxation 
time (IVRT) and myocardial tissue Doppler septal early diastolic filling velocity (E’), and was 
graded according to Nishimura and Tajik
30
: Grade 1=impaired relaxation with normal filling 
pressure, Grade 1a=impaired relaxation pattern with increased filling pressure, Grade 
2=pseudonormalized pattern, Grade 3= restrictive pattern.  Transmitral flow was acquired 
from the apical four-chamber view with the sample volume placed at the level of the tips of 
mitral leaflets.  From these traces E/A ratio, E deceleration time (DT), A wave duration and 
IVRT were determined.  Pulmonary venous flow was acquired from the same view by placing 
the sample volume within the right upper pulmonary vein.  From this trace peak systolic 
forward flow, diastolic forward flow, atrial reversal flow duration and peak velocity were 
measured. 
 
Color tissue Doppler imaging 
 
Real time color Doppler myocardial imaging data were obtained in the apical four-
chamber view.  Mitral annular velocities [peak systolic velocity, peak early diastolic filling 
velocity (E’), peak late diastolic velocity (A’) were recorded from the lateral and septal LV 
walls.  The width of the image sector and the depth of the imaging were adjusted to achieve a 
frame rate more than 180 frames/s.  Pulse repetition frequency was set at the lowest possible 
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level without aliasing.  To ensure an appropriate alignment of the Doppler beam with the 
myocardial segment of interest an insonation angle not exceeding 20
o
 was maintained. 
 
Statistical analysis 
 
All variables are expressed as mean+SD.  
One-way analysis of variance (ANOVA) was used for comparisons of patient 
characteristics as well as of oxidative stress and LV mass parameters followed by Tukey’s 
multiple comparisons test. The Kruskal–Wallis one-way analysis of variance was performed 
if Bartlett’s test indicated heterogeneity of variances followed by Student’s two-tailed t-test 
with Welch's correction. All tests were two-sided, and the level of significance was set at 
p<0.05.  The Hardy-Weinberg equilibrium was assessed and comparisons of the allele 
frequencies between groups and the deviation of these allele frequencies from Hardy-
Weinberg equilibrium were made using the chi-square test.  The analysis of association of the 
calculated genetic score based on MAFs of the investigated SNPs indicating predisposition 
for OXS with the presence of LV diastolic dysfunction was based on 95%CI for the disease 
odds ratio calculated according to Bland and Altman 2000
31
. 
Multivariate logistic regression analysis was carried out with adjustment for age, 
gender, smoking status, obesity (BMI ≥30 kg/m2), levels of HDL and LDL cholesterol and 
glomerular filtration rate. 
Pairwise linkage statistics were tested with the Arlequin software package
32
.  This 
excluded SNP pairs with independent occurrence.  Pairwise linkage disequilibrium (LD) 
statistics [quantified by Lewontin’s coefficient (D’) and r2 values] were tested through the 
detected linkages in Arlequin output with the standard method
33
.  This was compared with the 
latest data found in the HapMap database for general Caucasian population. 
12 
 
 
Statistical analysis was performed using GraphPad Prism5 (GraphPad Software Inc., 
San Diego, CA, USA), STATISTICA (version 11; StatSoft, Inc., Tulsa, Oklahoma, USA) and 
Statistical Package for the Social Sciences (version 22 for Windows; SPSS, Inc., Chicago, 
Illinois, USA). 
 
Results 
 
Patient characteristics 
 
Hypertensive patients with (HTDD+) or without LV diastolic dysfunction (HTDD-) 
and healthy controls had similar gender distribution, height, body weight, body surface area, 
diastolic blood pressure, heart rate, estimated glomerular filtration rate, HDL-cholesterol and 
hemoglobin concentrations.  Medication was similar in the two hypertensive groups (Table 1).  
There was no difference in age between the control and the whole hypertensive patient group 
(66.1+4.4 vs. 69.4+7.7 years, the latter data are not shown in Table 1), however, patients in 
the HTDD+ group were slightly older than those in the control and HTDD- groups. The body 
mass index (BMI) was higher and the systolic blood pressure was similarly elevated in both 
patient groups vs. the control group.  The serum creatinine value was higher in the HTDD+ 
group compared with the control group (Table 1).  The LDL-cholesterol was decreased in a 
borderline significant (p=0.0558) fashion in the HTDD- group and significantly in the 
HTDD+ group compared with controls, probably due to the fact that greater number of 
patients received statins in the hypertensive groups.  The systolic blood pressure was similarly 
elevated in both patient groups vs. the control group (Table 1). 
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LV diastolic dysfunction 
 
At the baseline examination LV diastolic dysfunction was not found in 38/94(40%) of 
patients with hypertension and normal EF (HTDD- group) and 56/94(60%) patients had mild, 
Grade 1 (54 patients) or Grade 1a (2 patients) LV diastolic dysfunction (HTDD+ group). 
 
LV mass 
 
LV mass (LVM) increased in the HTDD+ group compared with the control and 
HTDD- groups, while LVM was similar in the HTDD- and control groups.  LVM/body 
surface area (BSA) increased in both patient groups versus the controls, and in the HTDD+ 
group versus the HTDD- group.  LVM/BMI increased in the HTDD+ group versus the 
controls and in a borderline significant manner (p=0.063) in the HTDD+ versus the HTDD- 
group (Table 2)
27
. 
 
Association of the investigated individual gene polymorphisms with hypertension and 
LV diastolic dysfunction 
 
Minor allele frequency distribution 
 
After all 6 SNPs were assessed, we confirmed that all alleles were in Hardy-Weinberg 
equilibrium.  In none of the investigated individual SNPs a significant between-groups 
difference in MAFs was found (Table 3) 
 
GTPCH-1 Haplotype analysis 
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Our linkage disequilibrium analysis (these data are not shown) demonstrated a strong 
linkage among all four tested GTPCH SNPs according to the results published by Doehring 
A. et al.
13
  and to the data of the latest HapMap database. 
 
Combined effect of oxidative stress and BH4 metabolism associated SNPs on 
hypertension and LV diastolic dysfunction 
 
As it was expected, none of the investigated individual SNPs had significantly 
different MAF compared with controls and was significantly associated with hypertension and 
LV diastolic dysfunction.  Therefore, we devised a genetic score based on the total number of 
minor alleles of the investigated SNPs in each subject characterizing predisposition to OXS.  
The distribution of genetic score in different groups is shown in Table 4 demonstrating the 
decrease of the percentage of low risk and increase of the percentage of high risk patients for 
OXS in line with the presence of hypertension and LV diastolic dysfunction.  Patients with a 
high genetic score indicating predisposition to OXS had a significantly increased risk for 
HTDD+ (presence of LV diastolic dysfunction) [odds ratio=OR (95%CI): 4.05 (1.23-13.40); 
p=0.023] even after adjustment for age, gender, smoking status, obesity, levels of HDL and 
LDL cholesterol and glomerular filtration rate (adjusted OR (95% CI): 4.79 (1.12-20.54); 
p=0.035).  Patients with a high genetic score showed only a trend for increased risk for 
hypertension without LV diastolic dysfunction (Table 5). 
 
Protein carbonylation and plasma BH4 and total biopterin levels 
 
Compared with the controls protein carbonylation (PC) and plasma BH4 levels were increased 
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both in the HTDD- and HTDD+ groups and the plasma total biopterin (=BH4+BH2+biopterin) 
level was increased in the HTDD+ group (Table 2).
27
 
 
Discussion 
 
Main findings 
 
In this study we demonstrated that in patients with hypertension and normal EF there 
may be a genetic predisposition to OXS, which increases in line with the presence of LV 
diastolic dysfunction even after adjustment for age, gender, smoking habits, obesity, HDL and 
LDL-cholesterol levels and glomerular filtration rate in multiple logistic regression analysis.  
LV mass in itself or indexed to BSA or BMI increased in parallel with the presence of LV 
diastolic dysfunction in our patients as well.  Since the development of LV diastolic 
dysfunction and hypertrophy are important markers of the transition of hypertensive heart 
disease to HFPEF
4
 our results suggest that the greater number of prooxidant alleles is present 
in a subject with hypertension, the greater might be the likelihood of the transition of 
hypertensive heart disease to HFPEF.  In fact, we verified the presence of OXS in patients 
with hypertension and normal EF by the measurement of increased protein carbonylation and 
increased plasma BH4 and total biopterin levels
27
.  Increased plasma BH4 and total biopterin 
might suggest OXS is due to myocardial NOS uncoupling, because there is some evidence 
that increased plasma BH4 level is associated with decreased vascular (and probably tissue) 
BH4 level
7,8
, which causes NOS uncoupling, and in animal models of HFPEF myocardial 
NOS uncoupling as the most likely source of OXS was elegantly verified
5,6
.  To the best of 
our knowledge so far only the single nucleotide polymorphisms of individual genes encoding 
enzymes related to OXS were studied in hypertensive patients and this is the first study with 
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the aim to investigate the genetic predisposition of hypertensive patients to OXS. 
 
The rationale behind the selection of investigated gene polymorphisms 
 
The common feature of all investigated gene polymorphisms in this study was that 
they have been related to both endothelial dysfunction or hypertension and OXS and the 
function of enzymes encoded by the genes of the investigated SNPs are connected to each 
other in the cellular defence against OXS.  We hypothesized that the prevalence of minor 
alleles related to increased OXS and endothelial dysfunction or hypertension will be greater in 
patients with hypertension without LV diastolic dysfunction (HTDD- group) vs. controls, and 
even greater in patients with hypertension and LV diastolic dysfunction (HTDD+ group) 
compared with controls and the HTDD- group.  This working hypothesis is also consistent 
with the assumption that the development of LV diastolic dysfunction is considered an 
important stage and marker of the transition of hypertensive heart disease to HFPEF, and as a 
corollary this transition process is at least partly genetically determined.  Our results 
confirmed these hypotheses, because the genetic score, based on the MAFs of the investigated 
individual SNPs, indicating predisposition to OXS increased in line with the presence of LV 
diastolic dysfunction. 
For any multigenic disorder it is always a problem to quantify the importance of 
certain genetic variants on the phenotype. Our genetic score is a simplified model for 
quantitative trait heritance. Our model characterized well the associated phenotype and may 
be a useful marker in the prediction of progression of LV diastolic dysfunction and transition 
of hypertensive heart disease to HFPEF. 
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Limitations 
 
In this study we tested only a few (six) SNPs that might be related to increased OXS, 
however the regulation of redox metabolism, the production and elimination of free radicals 
in cells is a far more complicated process, involving much more proteins and enzymes 
encoded by several genes.  
Although we verified a genetic predisposition in patients with hypertension and 
normal EF to OXS in line with the presence of their LV diastolic dysfunction, the exact 
pathophysiological mechanisms of this genetic predisposition and whether the increased 
genetic risk for OXS plays an important role in the transition of hypertensive heart disease to 
HFPEF remain to be clarified in further future studies. 
Statins and other drugs, such as renin-angiotensin system inhibitors and beta blockers, 
used in the treatment of hypertension might have decreased OXS in patients with 
hypertension compared to controls due to their antioxidant effect
34,35
. 
Another significant limitations of this study are the small sample size, especially in the 
control group, and the lack of a verification cohort, therefore these preliminary results need 
further verification in a greater patient population with the application of a separate 
verification cohort. 
 
Conclusions 
 
We verified an increased OXS in hypertensive patients with normal LVEF, a potential 
precursor condition of HFPEF, which may be partly genetically determined.  A high genetic 
risk of OXS was significantly associated with the presence of LV diastolic dysfunction even 
after adjustment for confounding variables.  The genetic score devised to indicate 
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predisposition to OXS, which was based on the MAFs of 6 investigated SNPs of genes 
encoding enzymes related to OXS, BH4 metabolism and NOS function, together with LV 
diastolic dysfunction, LVM and atrial dysfunction might be a useful marker of the transition 
of hypertensive heart disease to HFPEF. 
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Table 1.^  Patient characteristics 
 
                                       Controls                            HTDD-                                HTDD+ 
                                         (n = 18)                            (n = 38)                                (n= 56) 
__________________________________________________________________________________ 
Age (years)                 66.1 ± 4.4                66.1 ± 5.6             71.6 ± 8.1*, ## 
 
Sex (F/M)      12/6        29/9                  33/23 
 
Duration of HT (years)                   0     11.5 ± 11.6             14.4 ± 12.2 
 
Height (cm)                168.7 ± 8.4              164.3 ± 7.5                               164.8 ± 8.6 
 
Weight (kg)   70.1 ± 13.2    74.3 ± 18             80.2 ± 25 
 
BMI (kg/m
2
)    24.6 ± 3.7    27.6 ± 5.8*             28 ± 4**, # 
 
BSA (m
2
)      1.8 ± 0.2      1.8 ± 0.2           1.8 ± 0.3 
 
Se creatinine (μmol/L)            71.6 ±14.8               70.3 ± 14.8            82.8 ± 25.2# 
 
eGFR (mL/min)              82.6 ± 19.9               88.4 ± 26.6            75.4 ± 27.1 
 
HDL-C (mmol/L)                     1.59+0.36                           1.55+0.39                              1.45+0.37 
 
LDL-C (mmol/L)                     3.38+0.72                           2.95+0.81                              2.79+1.12* 
 
SBP (mmHg)             129.5 ± 16.6             146.5 ± 16.2**          148.9 ± 17.9*** 
 
DBP (mmHg)    83.8 ± 9.1               85.9 ± 10.9            88.9 ± 10.8 
 
Heart rate (1/min)   71.1 ± 8.3              74.9 ± 9.3            72.2 ± 8.0 
 
Hemoglobin conc. (g/L)       140.9 ± 12.6            137.2 ± 13.1          138.9 ± 14.8 
 
Medications (number of patients) 
 
BB    1   22    30 
ACEI    0   19    35 
ARB    0   9    13  
CCB    0   15    27 
Diuretics   0   22    35 
Aldosterone antagonists   0   0    0 
Platelet inhibitors  0   14    24 
Statin    3   13    29 
PPI    2   10    8 
___________________________________________________________________________ 
^ Modified table from Ref. 27, 
*
 p<0.05, 
**
 p<0.01, 
***
 p<0.001 vs. control; 
#
 p<0.05, 
##
 p<0.01, 
### 
p<0.001 vs. 
HTDD- groups. HT=hypertension, BMI=body mass index, BSA=body surface area, eGFR=estimated glomerular 
filtration rate, HDL-C=HDL-cholesterol, LDL-C=LDL-cholesterol, SBP=systolic blood pressure, DBP=diastolic 
blood pressure, BB=beta-adrenergic receptor blocker, ACEI=angiotensin convertase enzyme inhibitor, 
ARB=angiotensin receptor blocker, CCB=calcium channel antagonist, PPI=proton pump inhibitor 
Table 2. Oxidative stress and LV mass parameters  
 
 
Parameter                                       Controls                     HTDD-                        HTDD+ 
                                                           (n=18)                       (n=38)                          (n=56) 
___________________________________________________________________________ 
 
PC (µmol/g)                                 0.191+0.131               0.306+0.214*               0.29+0.246* 
plasma BH4 (nmol/mL)               0.917+0.351               1.98+2.1**                   2.04+1.99** 
total biopterin (nmol/mL)           2.01+0.86                   3.05+2.8                       2.98+2.46* 
LVM (g)                                   166.2+38                    196.9+77.6                   226.4+66.2***
,#
 
LVM/BSA (g/m
2
)                       91.6+14.9                106.56+35.9*               122.7+31***
,#
 
LVM/BMI (g x m
2
/kg)                 6.779+1.218              7.255+2.608                 8.253+2.287** 
___________________________________________________________________________ 
*
 p<0.05, 
**
 p<0.01, 
***
 p<0.001 vs. control; 
#
 p<0.05, 
##
 p<0.01, 
### 
p<0.001 vs. HTDD- groups. 
 
Table 3. The minor allele frequencies of individual SNPs 
 
ref. MAF=The minor allele frequencies reported in the latest HapMap database for general 
Caucasian population, HW p=The p values indicating whether the MAFs of different SNPs 
are significantly different from or correspond to the Hardy-Weinberg equilibrium 
 
Gene SNP ref. MAF control MAF 
HTDD-  
MAF 
HTDD+  
MAF 
p HW p 
GTPCH rs841 0.23 0.13 0.11 0.16 0.580 0.702 
GTPCH rs8007267 0.48 0.13 0.12 0.14 0.907 0.927 
GTPCH rs3783641 0.25 0.16 0.14 0.15 0.939 0.914 
GTPCH rs10483639 0.23 0.13 0.11 0.16 0.580 0.702 
MnSOD rs4880 0.46 0.69 0.57 0.50 0.161 0.792 
NOS3 rs1799983 0.34 0.19 0.27 0.29 0.485 0.727 
        
Table 4.  Genetic score distribution in the different groups 
 
                                                                    patient groups 
_______________________________________________________________________ 
 
 Genetic score             Controls                       HTDD-                      HTDD+ 
                                        n=16                            n=37                           n=54 
_______________________________________________________________________ 
 
 
          0                              3                                   3                                  8 
 
          1                              8                                  18                                11 
_______________________________________________________________________  
low risk for OXS:      11/16 (68.7%)          21/37 (56.8%)            19/54 (35.2%) 
_______________________________________________________________________ 
 
          2                              3                                    8                                21 
 
          3                              2                                    5                                  7 
 
          4                              0                                    3                                  7 
 
          5                              0                                    0                                  0 
_______________________________________________________________________ 
high risk for OXS:     5/16 (31.3%)            16/37 (43.2%)            35/54 (64.8%) 
_______________________________________________________________________ 
OXS=oxidative stress 
 
 
Table 5.  Association of genetic risk for oxidative stress with left ventricular diastolic 
function 
 
 Low risk High risk Odds ratio 
(95% CI) 
p 
value 
Adjusted odds 
ratio(95% CI)* 
p 
value 
 
Normotensive 
(n=16) 
 
11 (68.7%) 5 (31.3%) 1.0  1.0  
Hypertensive 
without diastolic 
dysfunction 
(n=37) 
 
21 (56.8%) 16 (43.2%) 1.68(0.48-5.80) 0.544 1.66(0.38-7.16) 0.498 
Hypertensive 
with diastolic 
dysfunction 
(n=54) 
19 (35.2%) 35 (64.8%) 4.05(1.23-13.4) 0.023 4.79(1.12-20.54) 0.035 
 
* Adjustment was carried out for age, gender, smoking status, obesity (BMI ≥30 kg/m2), 
levels of HDL and LDL cholesterol and glomerular filtration rate. 
 
